NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

阿爾茨海默氏病治療藥物市場研究報告:按診斷,治療方法,按2025年藥物分類預測-COVID-19的累積影響

Alzheimer's Therapeutics Market Research Report by Diagnostics, by Therapeutics, by Drug Class, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版商 360iResearch LLP 商品編碼 995366
出版日期 內容資訊 英文 187 Pages
商品交期: 最快1-2個工作天內
價格
阿爾茨海默氏病治療藥物市場研究報告:按診斷,治療方法,按2025年藥物分類預測-COVID-19的累積影響 Alzheimer's Therapeutics Market Research Report by Diagnostics, by Therapeutics, by Drug Class, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19
出版日期: 2021年06月01日內容資訊: 英文 187 Pages
簡介

阿爾茨海默氏病治療的全球市場預計將從2020年的4,832.18百萬美元增長到2025年底的6,971.38百萬美元。

COVID-19是前所未有的全球公共衛生突發事件,已影響到每個行業。預計在預測期內,這種長期影響將影響行業增長。我們正在進行的研究正在擴大研究範圍,以確保我們解決潛在的COVID-19問題和未來路徑。該報告提供了對COVID-19的見解,並考慮了消費者行為和需求,購買模式,供應鏈改路,當前市場趨勢以及政府的主要干預措施的變化。

該報告探討了阿爾茨海默氏病藥物市場,以及市場概況,診斷趨勢,藥物類別,藥物類別,地區,COVID-19的累積影響以及進入市場的公司的概況等。

目錄

第1章簡介

  • 調查目的
  • 市場細分和範圍
  • 調查對像年度
  • 貨幣和價格
  • 語言
  • 限制
  • 利益相關者

第2章調查方法

  • 調查過程
    • 定義:調查目的
    • 決策:調查設計
    • 準備:測量設備
    • 集合:數據源
    • 分析:數據解釋
    • 策定:數據驗證
    • 公開:調查報告
    • 重複:報告更新
  • 進行調查
    • 開始:調查過程
    • 計劃:創建調查計劃
    • 執行:調查實施
    • 驗證:發現和分析
    • 出版物:調查報告
  • 調查結果

第3章執行摘要

  • 簡介
  • 市場前景
  • 診斷前景
  • 毒品類別的展望
  • 治療藥物的前景
  • 區域展望
  • 競爭對手的展望

第4章市場概述

  • 簡介
  • COVID-19的累積效果

第5章市場洞察

  • 市場動態
    • 促進因素
    • 抑制因素
    • 市場機會
    • 挑戰
  • 波特五力分析
    • 新進入者的威脅
    • 替代威脅
    • 客戶的議價能力
    • 供應商的談判能力
    • 行業競爭

第6章全球Alzheimer病治療市場(按診斷)

  • 腦圖像
  • 阿爾茨海默氏病CFS測試

第7章,全球藥物治療阿爾茨海默氏病市場

  • 膽鹼酯□抑製劑
  • NMDA受體拮抗劑

第8章,按藥物類別劃分的全球阿爾茨海默氏病藥物市場

  • 膽鹼酯□抑製劑
  • NMDA [N-甲基-D-天冬氨酸]受體拮抗劑

第9章在美洲的阿爾茨海默氏病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章在亞太地區的阿爾茨海默氏病治療市場

  • 澳大利亞
  • 中國
  • 印度
  • 印度尼西亞
  • 日本
  • 馬來西亞
  • 菲律賓
  • 韓國
  • 泰國

第11章歐洲,中東/非洲阿爾茨海默氏病藥物市場

  • 法國
  • 德國
  • 意大利
  • 荷蘭
  • 卡塔爾
  • 俄羅斯
  • 沙特阿拉伯
  • 南非
  • 西班牙
  • 阿拉伯聯合酋長國
  • 英國

第12章競爭情況

  • FPNV定位矩陣
    • 象限
    • 經營策略
    • 產品滿意度
  • 市場排名分析
  • 市場份額分析
  • 競爭性SWOT分析
  • 競爭情況
    • 併購
    • 協議,合作和夥伴關係
    • 推出和增強新產品
    • 投融資
    • 獎賞,表彰,擴張

第13章企業可用性概況

  • AbbVie
  • Alector
  • Altoida AG
  • Aphios Corporation
  • Applied BioMath, LLC
  • Asklepios BioPharmaceutical, Inc.
  • Codiak Biosciences
  • Cortexyme
  • D&D Pharmatech
  • Denali Therapeutics
  • Genentech
  • Ionis Pharmaceuticals Inc
  • Verge Genomics
  • Voyager Therapeutics
  • vTv Therapeutics
  • Wren Therapeutics

第14章附錄

  • 討論指南
  • 許可證和價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MRR-A77F2EE7AAEF

The Global Alzheimer's Therapeutics Market size was estimated at USD 4,832.18 Million in 2020 and expected to reach USD 5,223.86 Million in 2021, at a Compound Annual Growth Rate (CAGR) 8.44% to reach USD 7,859.19 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Alzheimer's Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Diagnostics, the Alzheimer's Therapeutics Market was studied across Brain Imaging and CFS Test for Alzheimer's Disease.

Based on Therapeutics, the Alzheimer's Therapeutics Market was studied across Cholinesterase Inhibitors and NMDA Receptor Antagonists.

Based on Drug Class, the Alzheimer's Therapeutics Market was studied across Cholinesterase Inhibitors and NMDA [N-methyl-D-aspartate] Receptor Antagonist.

Based on Geography, the Alzheimer's Therapeutics Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Alzheimer's Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Alzheimer's Therapeutics Market, including AbbVie, Alector, Altoida AG, Aphios Corporation, Applied BioMath, LLC, Asklepios BioPharmaceutical, Inc., Codiak Biosciences, Cortexyme, D&D Pharmatech, Denali Therapeutics, Genentech, Ionis Pharmaceuticals Inc, Verge Genomics, Voyager Therapeutics, vTv Therapeutics, and Wren Therapeutics.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Alzheimer's Therapeutics Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Alzheimer's Therapeutics Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Alzheimer's Therapeutics Market?
  • 4. What is the competitive strategic window for opportunities in the Global Alzheimer's Therapeutics Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Alzheimer's Therapeutics Market?
  • 6. What is the market share of the leading vendors in the Global Alzheimer's Therapeutics Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Alzheimer's Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Diagnostics Outlook
  • 3.4. Drug Class Outlook
  • 3.5. Therapeutics Outlook
  • 3.6. Geography Outlook
  • 3.7. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of Alzheimer's coupled with better healthcare facilities
      • 5.1.1.2. Development and availability of pipeline drugs
      • 5.1.1.3. Growing technologies for detection by early diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. Capital intensive treatment for Alzheimer's
      • 5.1.2.2. Increasing chances in failure of late-state drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Intense research and development with the inclusion of cloud-based cognitive systems and artificial intelligence
      • 5.1.3.2. Development of novel biomarkers and emerging regenerative therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent drug approval process
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Alzheimer's Therapeutics Market, by Diagnostics

  • 6.1. Introduction
  • 6.2. Brain Imaging
  • 6.3. CFS Test for Alzheimer's Disease

7. Alzheimer's Therapeutics Market, by Therapeutics

  • 7.1. Introduction
  • 7.2. Cholinesterase Inhibitors
  • 7.3. NMDA Receptor Antagonists

8. Alzheimer's Therapeutics Market, by Drug Class

  • 8.1. Introduction
  • 8.2. Cholinesterase Inhibitors
  • 8.3. NMDA [N-methyl-D-aspartate] Receptor Antagonist

9. Americas Alzheimer's Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States
    • 9.6.1. California
    • 9.6.2. Florida
    • 9.6.3. Illinois
    • 9.6.4. New York
    • 9.6.5. Ohio
    • 9.6.6. Pennsylvania
    • 9.6.7. Texas

10. Asia-Pacific Alzheimer's Therapeutics Market

  • 10.1. Introduction
  • 10.2. China
  • 10.3. India
  • 10.4. Indonesia
  • 10.5. Japan
  • 10.6. Malaysia
  • 10.7. Philippines
  • 10.8. South Korea
  • 10.9. Thailand

11. Europe, Middle East & Africa Alzheimer's Therapeutics Market

  • 11.1. Introduction
  • 11.2. France
  • 11.3. Germany
  • 11.4. Italy
  • 11.5. Netherlands
  • 11.6. Qatar
  • 11.7. Russia
  • 11.8. Saudi Arabia
  • 11.9. South Africa
  • 11.10. Spain
  • 11.11. United Arab Emirates
  • 11.12. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
    • 12.1.1. Quadrants
    • 12.1.2. Business Strategy
    • 12.1.3. Product Satisfaction
  • 12.2. Market Ranking Analysis
  • 12.3. Market Share Analysis, By Quadrant
  • 12.4. Market Share Analysis, By Company
  • 12.5. Competitive Scenario
    • 12.5.1. Merger & Acquisition
    • 12.5.2. Agreement, Collaboration, & Partnership
    • 12.5.3. New Product Launch & Enhancement
    • 12.5.4. Investment & Funding
    • 12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles

  • 13.1. AbbVie
  • 13.2. Alector
  • 13.3. Altoida AG
  • 13.4. Aphios Corporation
  • 13.5. Applied BioMath, LLC
  • 13.6. Asklepios BioPharmaceutical, Inc.
  • 13.7. Codiak Biosciences
  • 13.8. Cortexyme
  • 13.9. D&D Pharmatech
  • 13.10. Denali Therapeutics
  • 13.11. Genentech
  • 13.12. Ionis Pharmaceuticals Inc
  • 13.13. Verge Genomics
  • 13.14. Voyager Therapeutics
  • 13.15. vTv Therapeutics
  • 13.16. Wren Therapeutics

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing
  • 14.3. Contact Details

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
  • FIGURE 4. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET: MARKET DYNAMICS
  • FIGURE 7. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 8. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2020 VS 2026 (%)
  • FIGURE 9. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2020 VS 2026 (USD MILLION)
  • FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2026
  • FIGURE 11. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY BRAIN IMAGING, 2018-2026 (USD MILLION)
  • FIGURE 12. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY BRAIN IMAGING, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 13. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY CFS TEST FOR ALZHEIMER'S DISEASE, 2018-2026 (USD MILLION)
  • FIGURE 14. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY CFS TEST FOR ALZHEIMER'S DISEASE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 15. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2020 VS 2026 (%)
  • FIGURE 16. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2020 VS 2026 (USD MILLION)
  • FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2026
  • FIGURE 18. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2026 (USD MILLION)
  • FIGURE 19. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 20. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2026 (USD MILLION)
  • FIGURE 21. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 22. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (%)
  • FIGURE 23. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (USD MILLION)
  • FIGURE 24. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2026
  • FIGURE 25. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2026 (USD MILLION)
  • FIGURE 26. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 27. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY NMDA [N-METHYL-D-ASPARTATE] RECEPTOR ANTAGONIST, 2018-2026 (USD MILLION)
  • FIGURE 28. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY NMDA [N-METHYL-D-ASPARTATE] RECEPTOR ANTAGONIST, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 29. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 30. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 31. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 32. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 33. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 34. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 35. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 36. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 37. CALIFORNIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 38. FLORIDA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 39. ILLINOIS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 40. NEW YORK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 41. OHIO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 42. PENNSYLVANIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 43. TEXAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 44. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 45. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 46. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 47. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 48. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 49. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 50. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 51. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 52. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 53. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 54. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 55. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 56. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 57. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 58. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 59. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 60. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 61. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 62. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 63. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 64. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 65. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 66. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 67. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 68. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 69. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 70. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 71. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 72. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ALZHEIMER'S THERAPEUTICS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY BRAIN IMAGING, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY CFS TEST FOR ALZHEIMER'S DISEASE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY NMDA [N-METHYL-D-ASPARTATE] RECEPTOR ANTAGONIST, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. CALIFORNIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. CALIFORNIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. CALIFORNIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. FLORIDA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. FLORIDA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. FLORIDA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. ILLINOIS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. ILLINOIS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. ILLINOIS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. NEW YORK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. NEW YORK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. NEW YORK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. OHIO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. OHIO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. OHIO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. PENNSYLVANIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. PENNSYLVANIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. PENNSYLVANIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. TEXAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. TEXAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. TEXAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 73. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 74. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 75. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 76. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 77. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 78. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 79. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 80. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 85. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 86. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 87. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 88. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 89. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 90. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 91. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 92. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 93. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 94. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 95. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 96. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 97. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 98. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 99. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 100. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 101. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 102. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 103. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 104. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 105. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 106. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 107. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 108. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 109. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 110. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 111. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 112. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 113. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 114. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 115. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 116. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 117. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 118. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET: SCORES
  • TABLE 119. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET: BUSINESS STRATEGY
  • TABLE 120. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET: PRODUCT SATISFACTION
  • TABLE 121. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET: RANKING
  • TABLE 122. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 123. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET: SHARE, BY COMPANY, 2020
  • TABLE 124. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET: MERGER & ACQUISITION
  • TABLE 125. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 126. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 127. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET: INVESTMENT & FUNDING
  • TABLE 128. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 129. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET: LICENSE & PRICING
  • TABLE 130. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET: CONTACT DETAILS